Early human immunodeficiency virus (HIV) infection in the HIV network for prevention trials vaccine preparedness cohort: Risk behaviors, symptoms and early plasma and genital tract virus load

Journal of Infectious Diseases

Volumn 183, Issue 1, 2001, Pages 23-35

  Celum, Connie L ^a   Buchbinder, Susan P ^c   Donnell, Deborah ^b   Douglas, J M ^e   Mayer, Kenneth ^f   Koblin, Beryl ^h   Marmor, Michael ⁱ   Bozeman, Sam ^g   Grant, Robert M ^c   Flores, Jorge ^j   Sheppard, H W ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^e Denver Department of Public Health ^*  (United States)

^f BROWN UNIVERSITY   (United States)

^g ABT ASSOCIATES   (United States)

^h NEW YORK BLOOD CENTER   (United States)

ⁱ NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PROTEINASE INHIBITOR;

ADULT; ARTICLE; FEMALE; GENITAL SYSTEM; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SEMINAL PLASMA; SEROCONVERSION; SEXUAL BEHAVIOR; VACCINATION; VIRUS LOAD; VIRUS MUTATION;

ACUTE DISEASE; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CERVIX UTERI; COHORT STUDIES; DEMOGRAPHY; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HOMOSEXUALITY, MALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, VIRAL; SEMEN; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASES; TIME FACTORS; VIRAL LOAD;

EID: 0035169692     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/317658     Document Type: Article

References (82)

1. Intermediate-size trials for the evaluation of HIV vaccine candidates: A workshop summary
2. Biological considerations in the development of a human immunodeficiency virus vaccine
3. Primary HIV infection: A public health opportunity
4. Role of the primary infection in epidemics of HIV infection in gay cohorts
5. Heterosexual transmission of human immunodeficiency virus: Variability of infectivity throughout the course of infection
6. Clinical and epidemiologic features of primary HIV infection
7. Biological and virologic characteristics of primary HIV infection
8. Viral load and heterosexual transmission of human immunodeficiency virus type 1
9. Identification of HIV-1 in semen following primary HIV-1 infection
10. HIV-1 viral load in blood, semen and saliva
11. High levels of human immuno-deficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa
12. Sexual transmission of HIV: Infectiousness and prevention
13. Reduction of concentration of HIV-1 in semen after treatment of urethritis: Implications for prevention of sexual transmission of HIV-1
14. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men
15. Transmission of antiretroviral-drug-resistant HIV-1 variants
16. HIV-1 drug resistance in newly infected individuals
17. Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion
18. Reduced antiretroviral drug susceptibility among patients with primary HIV infection
19. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States
20. Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: Risk behavior, seroincidence, and willingness to participate
21. Per-contact risk of human immunodeficiency virus transmission between male sexual partners
22. Sexual transmission of HIV
23. High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors
24. Sensitive method for the detection of infectious HIV in semen of seropositive individuals
25. Rapid and simple method for purification of nucleic acids
26. Quantitation of human immunodeficiency virus type 1 RNA in cell free seminal plasma: Comparison of NASBA with Amplicor reverse transcription-PCR amplification and correlation with quantitative culture
27. Rapid and sensitive viral culture method for human immunodeficiency virus type 1
28. Genetic relationships determined by a DNA heteroduplex mobility assay: Analysis of HIV-1 env genes
29. Maintaining the integrity of human immunodeficiency virus sequence databases
30. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples
31. Multiplexed biochemical assays with biological chips
32. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
33. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
34. The role of CCR5 and CCR2 polymorphisms in HIV-1 transmission and disease progression
35. Random-effects models for longitudinal data
36. Phenotypic and genotypic analysis of stavudine-resistant isolates of HIV-1
37. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
38. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
39. Incidence and prognostic significance of symptomatic primary human immunodeficiency virus type I infection in homosexual men
40. Acute primary HIV infection
41. Symptomatic primary infection due to human immunodeficiency virus type 1: Review of 31 cases
42. Severity and prognosis of acute human immunodeficiency virus type 1 illness: A dose-response relationship
43. Primary human immuno-deficiency virus type 1 infection: Clinical manifestations among women in Mombasa, Kenya
44. Predictors of rapid progression to AIDS in HIV-1 seroconverters
45. Risk of developing AIDS after primary acute HIV-1 infection
46. 6/L, AIDS, and death from AIDS?
47. HIV-1 infection in an individual homozygous for the CCR5 deletion allele
48. HIV-1 infection in a man homozygous for CCR5 Δ 32
49. HIV-1 infection in an individual homozygous for CCR5 Δ 32
50. Homozygous Δ 32 deletion of the CCR-5 chemokine receptor gene in an HIV-1-infected patient
51. HIV-1 infection in a heterosexual man homozygous for CCR-5 Δ32
52. An HIV-1-infected individual homozygous for the CCR-5 Δ32 allele and the SDF-1 3′A allele
53. Frequency of a mutated CCR-5 allele (Δ32) among Italian healthy donors and individuals at risk of parenteral HIV infection
54. Association between CCR5 genotype and the clinical course of HIV-1 infection
55. Early protective effect of CCR-5 Δ 32 heterozygosity on HIV-1 disease progression: Relationship with viral load
56. The HIV type 1 coreceptor CCR5 and its role in viral transmission and disease progression
57. HIV-infected individuals with the CCR Δ32/CCR5 genotype have lower HIV RNA levels and higher CD4 cell counts in the early years of the infection than do patients with the wild type
58. HIV-1-infected long-term slow progressors heterozygous for Δ32-CCR5 show significantly lower plasma viral load than wild-type slow progressors
59. + T lymphocytes, and the chemokine receptors CCR5 and CCR2b on HIV disease progression in hemophiliacs. Hemophilia Growth and Development Study
60. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T cell decline in a cohort of HIV-seropositive individuals
61. Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study
62. Serum levels of human immunodefciency virus type 1 (HIV-1) RNA after seroconversion: A predictor of long-term mortality in HIV infection
63. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion
64. Sex differences in longitudinal human immunodeficiency virus type 1 RNA levels among seroconverters
65. Longitudinal human immunodeficiency virus type 1 load in the Italian seroconversion study: Correlates and temporal trends of virus load
66. HIV-1 in semen: Determination of proviral and viral titres compared to blood, and quantification of semen leukocyte populations
67. Detection and quantification of HIV-1 in semen: Identification of a subpopulation of men at high potential risk of viral sexual transmission
68. Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: Evidence for compartmentalization of HIV-1 between semen and blood
69. Human immunodeficiency virus type 1 shedding pattern in semen correlates with the compartmentalization of viral quasi species between blood and semen
70. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy
71. Sexually transmitted diseases and human immuno-deficiency virus infection: Cause, effect, or both?
72. Rebound of seminal HIV-1 viral load associated with sexually transmitted diseases (STDs) after virologic suppression by antiretroviral therapy
73. Transmission of zidovudine-resistant HIV-1 through heterosexual contacts
74. Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance
75. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors
76. Transmission of zidovudine-resistant HIV during a bloody fight
77. Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine
78. Transmission of zidovudineresistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: Characteristics and natural history of the virus
79. Transmission of HIV-1 resistant to multiple reverse transcriptase inhibitors and protease inhibitors
80. Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type I infection
81. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
82. Treatment of primary HIV-1 infection with combination antiretroviral therapy